Victoria Stewart
Investor Relations Contact bij VERONA PHARMA PLC
Oorsprong van het eerstegraads netwerk van Victoria Stewart
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 28 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Victoria Stewart via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| BAXTER INTERNATIONAL INC. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
| BAYER AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| AEROCRINE AB | Electronic Equipment/Instruments | Compliance Officer | |
| Bayer Pharmaceuticals Corp. | Director of Finance/CFO Chief Tech/Sci/R&D Officer | ||
| UNIVERSAL COAL PLC | Coal | Director/Board Member | |
| HERENCIA RESOURCES PLC | Investment Trusts/Mutual Funds | Corporate Secretary | |
| PANTHEON RESOURCES PLC | Oil & Gas Production | Corporate Secretary | |
| NORTH RIVER RESOURCES PLC. | Other Metals/Minerals | Corporate Secretary | |
Social Bicycles, Inc.
 Social Bicycles, Inc. Packaged SoftwareTechnology Services Social Bicycles, Inc. provides bike share technology services. It uses mobile technology and GPS to enable affordable, scalable, and intelligent bike-sharing networks. The company was founded by Ryan Rzepecki in 2011 and is headquartered in New York, NY. | Packaged Software | Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Xention Pharma Ltd.
 Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| University of Uppsala | College/University | Graduate Degree | |
| ALBA MINERAL RESOURCES PLC | Precious Metals | Corporate Secretary | |
| University of Lund | College/University | Doctorate Degree | |
Takeda A/S
 Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Financial Conglomerates | Chief Tech/Sci/R&D Officer | |
| The University of Western Australia | College/University | Graduate Degree | |
| CAPITAL METALS PLC | Agricultural Commodities/Milling | Corporate Secretary | |
| The Royal College of Physicians | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
| Hahnemann University | College/University | Doctorate Degree | |
S*BIO Pte Ltd.
 S*BIO Pte Ltd. Pharmaceuticals: MajorHealth Technology S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. | Pharmaceuticals: Major | Chief Executive Officer | |
Baxter BioScience Corp.
 Baxter BioScience Corp. BiotechnologyHealth Technology Baxter BioScience Corp. provides biopharmaceutical and vaccines services. It offers a portfolio of therapeutic proteins derived from either human plasma or recombinant technology. The company is headquartered in Beltsville, MD. | Biotechnology | Chief Tech/Sci/R&D Officer | |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
| University of Gothenburg | College/University | Doctorate Degree | |
Sahlgrenska Universitetssjukhuset
 Sahlgrenska Universitetssjukhuset Hospital/Nursing ManagementHealth Services Sahlgrenska Universitetssjukhuset engages in the provision of basic and emergency medical care. It offers specialized care, pediatrics, transplant activity, treatment of cardiovascular diseases, immunology, and vaccine research. Its hospital provides an infrastructure necessary for teaching and research. The company was founded on January 1, 1997 and is based in Gothenburg, Sweden. | Hospital/Nursing Management | Corporate Officer/Principal | |
| ALEXIUM INTERNATIONAL GROUP LIMITED | Chemicals: Specialty | Director/Board Member | |
| Nycomed Asset Management GmbH | Corporate Officer/Principal | ||
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Director/Board Member | |
Royal College of General Practitioners
 Royal College of General Practitioners Other Consumer ServicesConsumer Services The Royal College of General Practitioners is a professional membership body for family doctors in the UK and overseas. The non-profit company is based in London, UK and has subsidiaries in the United Kingdom. The British company is committed to improving patient care and clinical standards. The RCGP offers a fellowship program, which is the highest level of membership and exemplifies their motto "cum scientia caritas". The company also provides accreditation for high-quality resources and activities relevant to general practitioners. The Daffodil Standards is a free, evidence-based framework to help practices self-assess and consistently offer the best end of life and bereavement care. The RCGP represents the interests of established GPs and acts as a conduit for local matters to be raised at national meetings. | Other Consumer Services | Corporate Officer/Principal | |
Nycomed Pharma Pvt Ltd.
 Nycomed Pharma Pvt Ltd. Miscellaneous Commercial ServicesCommercial Services Nycomed Pharma Pvt Ltd. engages in drug research and development. The company was founded on May 9, 2003 and is headquartered in Mumbai, India. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
| Landgate | Director/Board Member | ||
| Zydus Nycomed Healthcare Pvt Ltd. | Director/Board Member | ||
| IOG | Oil & Gas Production | Corporate Secretary | |
| CROSSWORD CYBERSECURITY PLC | Packaged Software | Corporate Secretary | |
| PEXA AB | Medical Specialties | Director/Board Member | |
| DOVA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Chief Executive Officer General Counsel Human Resources Officer Chief Tech/Sci/R&D Officer | |
| KALVISTA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chairman | |
| INOZYME PHARMA, INC. | Pharmaceuticals: Major | Director/Board Member | |
| HARMONY BIOSCIENCES HOLDINGS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Stargazer Pharmaceuticals, Inc.
 Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member | |
Opterion Health AG
 Opterion Health AG Medical/Nursing ServicesHealth Services Opterion Health AG is a Swiss company that focuses on bringing innovation to dialysis care and fostering home dialysis to improve the quality of life for patients suffering from end-stage renal disease (ESRD). Opterion Health is based in Muttenz, CH. The private company aims to increase the survival rates of people with ESRD and reduce healthcare costs. The company was founded in 2012 by Guido Grentzmann, and the CEO is Bjorn Englund. | Medical/Nursing Services | Chairman Director/Board Member | |
Reset Pharmaceuticals, Inc.
 Reset Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reset Pharmaceuticals, Inc. is a clinical-stage biotechnology company that focuses on developing and commercializing novel treatments for patients suffering from mental illness related to life-altering diseases. Reset Pharmaceuticals is based in Great Neck, NY and was founded by Philip Taub and Jan-Anders Karlsson. The company's lead product candidate, the oral psilocybin, is being developed to treat demoralization syndrome in patients with cancer. Reset Pharma has a highly experienced team with a strong track record of successful development, approvals, and launches of neuroscience drugs. The company also has a scientific advisory board of key opinion leaders in psychiatry, oncology, and psychedelics, as well as a strategic advisory board of business leaders and financial experts. | Pharmaceuticals: Major | Founder Director/Board Member | |
| University of North Carolina at Chapel Hill | College/University | Graduate Degree Graduate Degree Doctorate Degree |
Statistieken
Internationaal
| Verenigd Koninkrijk | 17 |
| Verenigde Staten | 15 |
| Zweden | 9 |
| Duitsland | 5 |
| Australië | 3 |
Sectoraal
| Health Technology | 20 |
| Consumer Services | 9 |
| Energy Minerals | 4 |
| Non-Energy Minerals | 3 |
| Technology Services | 3 |
Operationeel
| Director/Board Member | 129 |
| Corporate Officer/Principal | 58 |
| Independent Dir/Board Member | 35 |
| Corporate Secretary | 28 |
| Chairman | 24 |
Sterkste connecties
| Insiders | |
|---|---|
| Martin Edwards | 38 |
| Mahendra Shah | 35 |
| Ben Harber | 29 |
| Rishi Gupta | 29 |
| David Ebsworth | 26 |
| Sven Anders Ullman | 19 |
| Piers John Morgan | 18 |
| Ken Cunningham Cunningham | 17 |
| David Moskowitz | 15 |
| Christina Ackermann | 15 |
| Mark Hahn | 13 |
| Vikas Sinha | 13 |
| David Zaccardelli | 10 |
| Jan-Anders Karlsson | 8 |
| Desiree Luthman | 7 |
- Beurs
- Insiders
- Victoria Stewart
- Bedrijfsconnecties
